Investigation launched into ADMA Biologics for alleged channel-stuffing to boost revenues amid falling demand.

Berger Montague PC is investigating ADMA Biologics' Board of Directors for possible breaches of fiduciary duty related to alleged channel-stuffing practices. The firm suspects ADMA may have artificially inflated revenue growth despite declining demand for its main product, ASCENIV, an immune globulin therapy. This probe could impact shareholder confidence and the company's market standing. Investors are encouraged to contact Berger Montague for more information or to participate in the investigation.